Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

by Team Lumida
June 5, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Apparel returns are surging as GLP-1 users rapidly lose weight, with one online retailer reporting a 50% increase in returns in the past year — a direct hit to gross margins that can cost a $1 billion retailer $20 million or more.
  • The share of apparel exchanges where shoppers sized down hit a record 14.6% in 2025, up for three consecutive years, according to a review of 38 retailers by returns manager Narvar.
  • Returns for medium, large, and extra-large items are rising the fastest, according to Impact Analytics, as GLP-1 users cycle through multiple sizes while their bodies change — sometimes dropping a full size every few weeks at peak weight loss.
  • Retailers are responding with higher restocking fees (one doubling its fee to 20%), stricter size chart guidance, and smaller-size inventory increases — but the structural problem is growing as GLP-1s become cheaper and more accessible via pill form.

What Happened?

America’s apparel retailers are grappling with a new source of margin pressure: the mass adoption of GLP-1 weight-loss medications. At peak weight loss, users of drugs like Zepbound can drop a full clothing size every month, and they’re responding by ordering multiple sizes simultaneously and returning what doesn’t fit. Online budget suit retailer FlexSuits has seen a 50% increase in returns over the past year, with founder Farnam Elyasof flagging multi-size orders as a “red flag.” The problem is particularly acute in mid-range sizes: returns for medium, large, and XL items are rising fastest, per Impact Analytics, as GLP-1 users shop while uncertain about where their bodies will land.

Why It Matters?

Returns are among the most destructive forces in retail economics. Shipping, labor, and warehousing costs compound quickly, and out-of-season items returned after their selling window must be marked down. For a $1 billion apparel company with a typical 20% return rate, a 5-to-10 percentage point increase in returns can wipe $20 million off gross margins. The GLP-1 return wave isn’t a blip — it’s structural. An estimated 60% of returns at one women’s brand now cite “item too big” or weight loss as the reason, up from 30-40% a year ago. As GLP-1s become cheaper and expand to a pill form, the user base — and the return rate — will likely grow further. Retailers from Levi Strauss to Costco and Walmart are all actively studying the shift.

What’s Next?

Retailers are adapting on multiple fronts: higher restocking fees (one retailer doubled its fee to 20% of purchase price), more detailed size guidance, and shifts in inventory mix toward smaller sizes. Some are applying stricter return policies to reduce “bracket buying” — ordering multiple sizes with intent to return. But the fundamental challenge remains: a consumer base in active physical transition is inherently difficult to serve with fixed-size merchandise. As GLP-1 adoption widens, the retailers best positioned will likely be those with strong loyalty data, flexible return economics, or direct-to-consumer models where they can engage customers through their weight-loss journey rather than just at the point of purchase.

Source: The Wall Street Journal

Previous Post

Trump Officials Are Feuding Over Whether a Policy Loophole Let China Buy Nvidia’s Most Advanced AI Chips

Next Post

Apple’s Bet on AI Supremacy Starts With Finally Fixing Siri — Using Google’s Technology

Recommended For You

Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

by Team Lumida
4 hours ago
Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

Novo Nordisk's Wegovy pill has seized 89% of new oral obesity pill prescriptions since its January 2026 launch, leaving Eli Lilly's Foundayo — launched in April — with...

Read more

Information Blocking in Healthcare Is Down — But a Stubborn Minority of IT Vendors Keep Doing It Routinely

by Team Lumida
2 days ago
doctor holding red stethoscope

The share of health information exchanges reporting instances of information blocking fell from over 90% in 2019 to 71% in 2025, according to new ONC data — but...

Read more

Novo Nordisk Squeezes Suppliers for Discounts as Eli Lilly Eats Its Lunch in the Obesity Drug Market

by Team Lumida
2 weeks ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has written to suppliers seeking price discounts to protect its cost base as it fights to claw back market share lost to Eli Lilly in the...

Read more

Medicare Launches $50/Month Weight-Loss Drug Coverage Today — With Caveats

by Team Lumida
2 weeks ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Medicare's "Bridge" program kicks off July 1, offering Wegovy and Zepbound to 12.5–20 million eligible seniors at a $50 monthly copay — down from up to $450 cash...

Read more

FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

by Team Lumida
3 weeks ago
FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

The FDA agreed to reverse its rejection of Regenxbio's Navsunli gene therapy for Hunter syndrome — the third rare-disease drug reversal under new FDA leadership, marking a retreat...

Read more

Nvidia Partners With Abridge to Build an AI Model Trained on Real Doctor-Patient Conversations

by Team Lumida
1 month ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia and AI medical note-taking startup Abridge are jointly developing a clinical AI model trained on de-identified doctor-patient conversations, using Nvidia's open Nemotron models as a base —...

Read more

Nearly 90% of Americans Have It and Don’t Know It: First Guidelines Issued for CKM Syndrome

by Team Lumida
1 month ago
people holding us a flag during daytime

The American Heart Association and three major medical societies published the first clinical guidelines for cardiovascular-kidney-metabolic syndrome — a cluster of interconnected conditions tied to excess body fat...

Read more

Employers Are Slashing GLP-1 Coverage as Costs Spiral — And Some Are Adding Weigh-Ins to Keep It

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

More than a quarter of large companies are adding new criteria for GLP-1 weight-loss coverage while 11% are dropping it altogether, as drug costs balloon and employers struggle...

Read more

Weight-Loss Drugs Like Ozempic May Also Slow Cancer — Four New Studies Show Striking Results

by Team Lumida
2 months ago
Eli Lilly and Novo Nordisk Shares Plunge Amid Ozempic Vision Loss Fears

GLP-1 drugs used for diabetes and obesity are linked to reduced tumor progression, lower cancer mortality, and decreased breast cancer risk across hundreds of thousands of patients in...

Read more

GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

by Team Lumida
2 months ago
GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

As 13 million Americans take GLP-1 drugs like Ozempic and Mounjaro, a growing body of research warns the drugs can cause up to 10% lean muscle loss —...

Read more
Next Post
Apple Store shop front

Apple's Bet on AI Supremacy Starts With Finally Fixing Siri — Using Google's Technology

Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Anthropic Calls for a Global Pause in Frontier AI Development, Warning of 'Recursive Self-Improvement' Risk

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Why Apple’s AI Approach May Save Its Reputation

Apple to Let Users Choose Claude, Gemini, or ChatGPT to Power iPhone AI Features in iOS 27

May 6, 2026
Tax-Loss Harvesting Surge: JPMorgan’s $15 Billion Windfall

JPMorgan Initiates Coverage of $6.1B Fintech Plaid Amid Rising Data Access Fee Tensions

August 7, 2025
Bitcoin Mining Stocks Outperform BTC in Early 2025, Network Strength Grows

The Year’s Hottest Crypto Trade Is Crumbling

November 10, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018